Antibody drug conjugates for treatment of breast cancer: novel targets and diverse approaches in ADC design

PA Trail, GM Dubowchik, TB Lowinger - Pharmacology & therapeutics, 2018‏ - Elsevier
Breast cancer is a heterogeneous group of malignancies with a spectrum of molecular
subtypes, pathologies and outcomes that together comprise the most common non …

Therapeutic targeting of DNA replication stress in Cancer

L Gu, RJ Hickey, LH Malkas - Genes, 2023‏ - mdpi.com
This article reviews the currently used therapeutic strategies to target DNA replication stress
for cancer treatment in the clinic, highlighting their effectiveness and limitations due to …

[HTML][HTML] Rapid microfluidic preparation of niosomes for targeted drug delivery

D Ag Seleci, V Maurer, F Stahl, T Scheper… - International journal of …, 2019‏ - mdpi.com
Niosomes are non-ionic surfactant-based vesicles with high promise for drug delivery
applications. They can be rapidly prepared via microfluidics, allowing their reproducible …

Development of a highly stable and targetable nanoliposomal formulation of topotecan

DC Drummond, CO Noble, Z Guo, ME Hayes… - Journal of controlled …, 2010‏ - Elsevier
Topotecan (TPT), a highly active anticancer camptothecin drug, would benefit from
nanocarrier-mediated site-specific and intracellular delivery because of a labile lactone ring …

Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity

C Alonso, M Fuertes, E Martín-Encinas, A Selas… - European Journal of …, 2018‏ - Elsevier
This work describes the synthesis of 1, 2, 3, 4-tetrahydroquinolinylphosphine oxides,
phosphanes and phosphine sulfides as well as that of quinolinylphosphine oxides and …

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

K Hashimoto, S Man, P Xu, W Cruz-Munoz… - Molecular cancer …, 2010‏ - aacrjournals.org
Low-dose metronomic chemotherapy has shown promising activity in many preclinical and
some phase II clinical studies involving various tumor types. To evaluate further the potential …

Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration …

S Padhi, MA Mirza, D Verma, T Khuroo, AK Panda… - Drug Delivery, 2016‏ - Taylor & Francis
Topotecan (TPT) is indicated against a variety of solid tumors, but has restricted clinical use
owing to associated pharmaceutical caveats. This study is focused at formulating a …

[HTML][HTML] Formulation and optimization of topotecan nanoparticles: in vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes

S Padhi, R Kapoor, D Verma, AK Panda… - Journal of Photochemistry …, 2018‏ - Elsevier
The study focuses on widening up the therapeutic perspective of anti-cancer therapy by
entrap** a hydrophilic anticancer drug, topotecan hydrochloride (TOPO) in biodegradable …

Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies

MZH Fadlullah, IKN Chiang, KR Dionne… - …, 2016‏ - pmc.ncbi.nlm.nih.gov
Emerging biological and translational insights from large sequencing efforts underscore the
need for genetically-relevant cell lines to study the relationships between genomic …

Synthesis and biological evaluation of indeno [1, 5] naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity

C Alonso, M Fuertes, M González, G Rubiales… - European Journal of …, 2016‏ - Elsevier
In an effort to establish new candidates with improved anticancer activity, we report here the
synthesis of various series of 7H-indeno [2, 1-c][1, 5]-naphthyridines and novel 7H-indeno …